Ziprasidone: An overview of efficacy and tolerability in the treatment of patients with an acute exacerbation of schizophrenia or schizoaffective disorder

被引：0
|
作者：
Keck, PE
Harrigan, EP
Reeves, KR
机构：
[1] UNIV CINCINNATI,COLL MED,DEPT PSYCHIAT,CINCINNATI,OH 45267
[2] PFIZER INC,PFIZER CENT RES,DEPT CLIN RES,GROTON,CT 06340
来源：
PSYCHOPHARMACOLOGY BULLETIN | 1997年 / 33卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：535 / 535
页数：1
相关论文
共 50 条
  • [31] Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder
    Simpson, GM
    Glick, ID
    Weiden, PJ
    Romano, SJ
    Siu, CO
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (10): : 1837 - 1847
  • [32] Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study
    Brook, S
    Walden, J
    Benattia, I
    Siu, CO
    Romano, SJ
    PSYCHOPHARMACOLOGY, 2005, 178 (04) : 514 - 523
  • [33] Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study
    Shlomo Brook
    Jeorg Walden
    Isma Benattia
    Cynthia O. Siu
    Steven J. Romano
    Psychopharmacology, 2005, 178 : 514 - 523
  • [34] Overview of ziprasidone tolerability in older patients
    Loebel, A
    Cohen, G
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 178 - 178
  • [35] The efficacy and safety of ziprasidone 80 mg/day and 160 mg/day in schizophrenia and schizoaffective disorder
    Daniel, D
    Reeves, K
    Harrigan, EP
    SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) : 204 - 204
  • [36] Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
    Zhang, Hongyan
    Li, Huafang
    Shu, Liang
    Gu, Niufan
    Wang, Gang
    Weng, Yongzhen
    Xie, Shiping
    Zhang, Xinbao
    Li, Ting
    Ma, Cui
    Yu, Wei
    Parsons, Bruce
    Schou, Manjula
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 77 - 85
  • [37] A pilot study of intramuscular ziprasidone in the short-term treatment of patients with acute exacerbation of schizophrenia
    Brook, S
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2000, 15 (07) : 521 - 524
  • [38] Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder
    Miceli, Jeffrey J.
    Tensfeldt, Thomas G.
    Shiovitz, Thomas
    Anziano, Richard
    O'Gorman, Cedric
    Harrigan, Rachel H.
    PHARMACOTHERAPY, 2010, 30 (02): : 127 - 135
  • [39] An overview of the treatment of schizoaffective disorder
    McElroy, SL
    Keck, PE
    Strakowski, SM
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 : 16 - 21
  • [40] Ziprasidone in treatment-resistant schizophrenia: Long-term efficacy and tolerability
    Dunn, J
    Kane, J
    Khanna, S
    Giller, E
    Rajadhyaksha, S
    Loebel, A
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 481 - 482
12345